Table 1. Baseline characteristics of patients in the NEONAB primary cohort.
| Characteristic | n | % |
|---|---|---|
| Age, years | ||
| Median | 51 | |
| Range | (35–77) | |
| ECOG | ||
| 0 | 39 | 98 |
| 1 | 1 | 2 |
| Ethnic group | ||
| Caucasian | 37 | 93 |
| Asian | 3 | 8 |
| Tumour pathology | ||
| Adenocarcinoma | 1 | 2 |
| Ductal no special type | 34 | 85 |
| Inflammatory | 1 | 2 |
| Lobular carcinoma | 1 | 2 |
| Mucinous carcinoma | 1 | 2 |
| Not specified | 2 | 5 |
| Oestrogen receptor status | ||
| Negative* | 22 | 55 |
| Positive | 18 | 45 |
| Progesterone receptor status | ||
| Negative* | 27 | 68 |
| Positive | 13 | 32 |
| HER2 status | ||
| Non-amplified | 25 | 63 |
| Amplified | 15 | 37 |
| Tumour grade | ||
| 2 | 14 | 35 |
| 3 | 22 | 55 |
| Not specified | 4 | 10 |
| Tumour stage+ | ||
| 2a | 10 | 25 |
| 2b | 12 | 30 |
| 3a | 14 | 35 |
| 3b | 3 | 8 |
| 3c | 1 | 2 |
*HR status deemed negative if <1% nuclei staining; + American Joint Committee on Cancer Breast Cancer Staging v.7; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor type 2